The Institute for Translational Medicine and Therapeutics (ITMAT) supports research at the interface of basic and clinical research focusing on developing new and safer therapeutics. ITMAT includes faculty, basic research space, and the Clinical and Translational Research Center (CTRC), which derives from the integration of the former General Clinical Research Center (GCRC) of both Penn and the Children's Hospital of Philadelphia (CHOP). ITMAT also offers research cores, educational programs (including a Masters in Translational Research), and research centers. These are designed to facilitate training and research from proof of concept in cellular and animal model systems across the translational divide to proof of concept and dose selection in humans.
ITMAT laboratories are housed within the Smilow Center for Translational Research.
The objectives of ITMAT are, (i) to provide an intellectual home and critical mass of researchers who pursue translational research, (ii) to expand the number of faculty pursuing translational research through recruitment, (iii) to expand this critical mass by educating existing faculty in translational research, and, (iv) to function as a single point of contact for Penn investigators and external investigators and agencies interested in pursuing translational research.
ITMAT includes more than 800 investigators from all schools at Penn, the Children's Hospital of Philadelphia, the Wistar Institute, the Monell Institute, and the University of Sciences in Philadelphia. As such, it represents a unique campus wide resource for those seeking collaborations and job placement in clinical and translational research. Funding for ITMAT comes from the partner institutions and the Clinical and Translational Science Award (CTSA) funded under the NIH Roadmap, and other sources of extramural support. The two major focus areas of this CTSA are, (i) Translational Therapeutics, and, (ii) Bridging the Pediatric - Adult divide in our understanding of physiology and disease.